WuXi Biologics sees no impact from addition to unverified list for U.S. exports
Reuters
Published Feb 07, 2022 09:36PM ET
Updated Feb 07, 2022 09:56PM ET
BEIJING (Reuters) - WuXi Biologics said in a statement on Tuesday on WeChat that two of its subsidiaries being put on the U.S. Commerce Department's "unverified list" will have no impact on its business or services to partners.
The company is pursuing interim measures to remove these subsidiaries from the list, said the statement.
The U.S. Commerce Department on Monday said it had added 33 entities in the People's Republic of China (PRC) to its unverified list for receiving U.S. exports. The department said it was taking the step as it was unable to establish how export items would be used by the entities.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.